351
|
Guiochon G, Beaver LA. Separation science is the key to successful biopharmaceuticals. J Chromatogr A 2011; 1218:8836-58. [DOI: 10.1016/j.chroma.2011.09.008] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2011] [Revised: 09/04/2011] [Accepted: 09/05/2011] [Indexed: 10/17/2022]
|
352
|
Pezzini J, Joucla G, Gantier R, Toueille M, Lomenech AM, Le Sénéchal C, Garbay B, Santarelli X, Cabanne C. Antibody capture by mixed-mode chromatography: A comprehensive study from determination of optimal purification conditions to identification of contaminating host cell proteins. J Chromatogr A 2011; 1218:8197-208. [DOI: 10.1016/j.chroma.2011.09.036] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2011] [Revised: 09/08/2011] [Accepted: 09/14/2011] [Indexed: 10/17/2022]
|
353
|
|
354
|
Borlido L, Azevedo A, Roque A, Aires-Barros M. Potential of boronic acid functionalized magnetic particles in the adsorption of human antibodies under mammalian cell culture conditions. J Chromatogr A 2011; 1218:7821-7. [DOI: 10.1016/j.chroma.2011.08.084] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2011] [Revised: 08/25/2011] [Accepted: 08/27/2011] [Indexed: 10/17/2022]
|
355
|
Rathore AS, Shirke A. RECENT DEVELOPMENTS IN MEMBRANE-BASED SEPARATIONS IN BIOTECHNOLOGY PROCESSES: REVIEW. Prep Biochem Biotechnol 2011; 41:398-421. [DOI: 10.1080/10826068.2011.613976] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
356
|
Bartlow P, Tiwari N, Beitle RR, Ataai MM. Evaluation of Escherichia coli proteins that burden nonaffinity-based chromatography as a potential strategy for improved purification performance. Biotechnol Prog 2011; 28:137-45. [DOI: 10.1002/btpr.703] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2011] [Revised: 07/28/2011] [Indexed: 11/12/2022]
|
357
|
Model simulation and experimental verification of a cation-exchange IgG capture step in batch and continuous chromatography. J Chromatogr A 2011; 1218:5195-204. [DOI: 10.1016/j.chroma.2011.05.103] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2011] [Revised: 05/24/2011] [Accepted: 05/30/2011] [Indexed: 11/21/2022]
|
358
|
Recombinant protein production by in vivo polymer inclusion display. Appl Environ Microbiol 2011; 77:6706-9. [PMID: 21803888 DOI: 10.1128/aem.05953-11] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A novel approach to produce purified recombinant proteins was established. The target protein is produced as polyhydroxyalkanoate (PHA) synthase fusion protein, which mediates intracellular formation of PHA inclusions displaying the target protein. After isolation of the PHA inclusions, the pure target protein was released by simple enterokinase digestion.
Collapse
|
359
|
Almodóvar EXP, Tao Y, Carta G. Protein adsorption and transport in cation exchangers with a rigid backbone matrix with and without polymeric surface extenders. Biotechnol Prog 2011; 27:1264-72. [DOI: 10.1002/btpr.643] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2011] [Revised: 04/07/2011] [Indexed: 11/08/2022]
|
360
|
Abstract
Sales of monoclonal antibody (mAbs) therapies exceeded $ 40 billion in 2010 and are expected to reach $ 70 billion by 2015. The majority of the approved antibodies are targeting cancer and autoimmune diseases with the top 5 grossing antibodies populating these two areas. In addition over 100 monoclonal antibodies are in Phase II and III of clinical development and numerous others are in various pre-clinical and safety studies. Commercial production of monoclonal antibodies is one of the few biotechnology manufacturing areas that has undergone significant improvements and standardization over the last ten years. Platform technologies have been established based on the structural similarities of these molecules and the regulatory requirements. These improvements include better cell lines, advent of high-performing media free of animal-derived components, and advances in bioreactor and purification processes. In this chapter we will examine the progress made in antibody production as well as discuss the future of manufacturing for these molecules, including the emergence of single use technologies.
Collapse
|
361
|
Hasegawa H, Wendling J, He F, Trilisky E, Stevenson R, Franey H, Kinderman F, Li G, Piedmonte DM, Osslund T, Shen M, Ketchem RR. In vivo crystallization of human IgG in the endoplasmic reticulum of engineered Chinese hamster ovary (CHO) cells. J Biol Chem 2011; 286:19917-31. [PMID: 21464137 DOI: 10.1074/jbc.m110.204362] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Protein synthesis and secretion are essential to cellular life. Although secretory activities may vary in different cell types, what determines the maximum secretory capacity is inherently difficult to study. Increasing protein synthesis until reaching the limit of secretory capacity is one strategy to address this key issue. Under highly optimized growth conditions, recombinant CHO cells engineered to produce a model human IgG clone started housing rod-shaped crystals in the endoplasmic reticulum (ER) lumen. The intra-ER crystal growth was accompanied by cell enlargement and multinucleation and continued until crystals outgrew cell size to breach membrane integrity. The intra-ER crystals were composed of correctly folded, endoglycosidase H-sensitive IgG. Crystallizing propensity was due to the intrinsic physicochemical properties of the model IgG, and the crystallization was reproduced in vitro by exposing a high concentration of IgG to a near neutral pH. The striking cellular phenotype implicated the efficiency of IgG protein synthesis and oxidative folding exceeded the capacity of ER export machinery. As a result, export-ready IgG accumulated progressively in the ER lumen until a threshold concentration was reached to nucleate crystals. Using an in vivo system that reports accumulation of correctly folded IgG, we showed that the ER-to-Golgi transport steps became rate-limiting in cells with high secretory activity.
Collapse
Affiliation(s)
- Haruki Hasegawa
- Department of Protein Science, Amgen Inc., Seattle, Washington 98119, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
362
|
Designing new monoclonal antibody purification processes using mixed-mode chromatography sorbents. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:836-43. [DOI: 10.1016/j.jchromb.2011.02.047] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2010] [Revised: 02/25/2011] [Accepted: 02/28/2011] [Indexed: 11/20/2022]
|
363
|
Konno Y, Aoki M, Takagishi M, Sakai N, Koike M, Wakamatsu K, Hosoi S. Enhancement of antibody production by the addition of Coenzyme-Q(10). Cytotechnology 2011; 63:163-70. [PMID: 21197574 PMCID: PMC3080474 DOI: 10.1007/s10616-010-9330-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2010] [Accepted: 12/17/2010] [Indexed: 11/30/2022] Open
Abstract
Recently, there has been a growing demand for therapeutic monoclonal antibodies (MAbs) on the global market. Because therapeutic MAbs are more expensive than low-molecular-weight drugs, there have been strong demands to lower their production costs. Therefore, efficient methods to minimize the cost of goods are currently active areas of research. We have screened several enhancers of specific MAb production rate (SPR) using a YB2/0 cell line and found that coenzyme-Q(10) (CoQ(10)) is a promising enhancer candidate. CoQ(10) is well known as a strong antioxidant in the respiratory chain and is used for healthcare and other applications. Because CoQ(10) is negligibly water soluble, most studies are limited by low concentrations. We added CoQ(10) to a culture medium as dispersed nanoparticles at several concentrations (Q-Media) and conducted a fed-batch culture. Although the Q-Media had no effect on cumulative viable cell density, it enhanced SPR by 29%. In addition, the Q-Media had no effect on the binding or cytotoxic activity of MAbs. Q-Media also enhanced SPR with CHO and NS0 cell lines by 30%. These observations suggest that CoQ(10) serves as a powerful aid in the production of MAbs by enhancing SPR without changing the characteristics of cell growth, or adversely affecting the quality or biological activity of MAbs.
Collapse
Affiliation(s)
- Yoshinobu Konno
- Bioprocess Research and Development Laboratories, Kyowa Hakko Kirin Co., Ltd., 100-1 Hagiwara-machi, Takasaki-shi, Gunma, 370-0013, Japan,
| | | | | | | | | | | | | |
Collapse
|
364
|
Jiang C, Scherfner S, Shukla AA. Demonstrating β-glucan and yeast peptide clearance in biopharmaceutical downstream processes. Biotechnol Prog 2011; 27:442-50. [DOI: 10.1002/btpr.568] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2010] [Revised: 11/22/2010] [Indexed: 11/06/2022]
|
365
|
Jiang C, Flansburg L, Ghose S, Jorjorian P, Shukla AA. Defining process design space for a hydrophobic interaction chromatography (HIC) purification step: application of quality by design (QbD) principles. Biotechnol Bioeng 2011; 107:985-97. [PMID: 20683852 DOI: 10.1002/bit.22894] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
The concept of design space has been taking root under the quality by design paradigm as a foundation of in-process control strategies for biopharmaceutical manufacturing processes. This paper outlines the development of a design space for a hydrophobic interaction chromatography (HIC) process step. The design space included the impact of raw material lot-to-lot variability and variations in the feed stream from cell culture. A failure modes and effects analysis was employed as the basis for the process characterization exercise. During mapping of the process design space, the multi-dimensional combination of operational variables were studied to quantify the impact on process performance in terms of yield and product quality. Variability in resin hydrophobicity was found to have a significant influence on step yield and high-molecular weight aggregate clearance through the HIC step. A robust operating window was identified for this process step that enabled a higher step yield while ensuring acceptable product quality.
Collapse
Affiliation(s)
- Canping Jiang
- Manufacturing Sciences & Technology, Bristol-Myers Squibb Co., East Syracuse, New York 13057, USA
| | | | | | | | | |
Collapse
|
366
|
Comparison of the chromatographic properties of IgG1 and IgG2 antibody subclasses. Biotechnol Appl Biochem 2011; 57:111-6. [DOI: 10.1042/ba20100205] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
367
|
Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. ADVANCES IN PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY 2011; 84:41-61. [DOI: 10.1016/b978-0-12-386483-3.00004-5] [Citation(s) in RCA: 132] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
|
368
|
Shinkazh O, Kanani D, Barth M, Long M, Hussain D, Zydney AL. Countercurrent tangential chromatography for large-scale protein purification. Biotechnol Bioeng 2010; 108:582-91. [DOI: 10.1002/bit.22960] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2010] [Revised: 09/11/2010] [Accepted: 09/16/2010] [Indexed: 11/10/2022]
|
369
|
Dhivya AP, Kumar BP, Prasanna RR, Jayaprakash NS, Vijayalakshmi MA. Purification of Monoclonal Antibodies from Cell-Culture Supernatant by Use of Anion-Exchange Convective Interaction Media (CIM) Monolithic Columns. Chromatographia 2010. [DOI: 10.1365/s10337-010-1787-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
370
|
Hou Y, Jiang C, Shukla AA, Cramer SM. Improved process analytical technology for protein a chromatography using predictive principal component analysis tools. Biotechnol Bioeng 2010; 108:59-68. [DOI: 10.1002/bit.22886] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
371
|
Mozziconacci O, Kerwin BA, Schöneich C. Exposure of a Monoclonal Antibody, IgG1, to UV-Light Leads to Protein Dithiohemiacetal and Thioether Cross-Links: A Role for Thiyl Radicals? Chem Res Toxicol 2010; 23:1310-2. [DOI: 10.1021/tx100193b] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Olivier Mozziconacci
- Department of Pharmaceutical Chemistry, 2095 Constant Avenue, University of Kansas, Lawrence, Kansas 66047, and Department of Analytical and Formulation Science, Process and Product Development, Amgen Inc., 1201 Amgen Court West, Seattle, Washington 98119
| | - Bruce A. Kerwin
- Department of Pharmaceutical Chemistry, 2095 Constant Avenue, University of Kansas, Lawrence, Kansas 66047, and Department of Analytical and Formulation Science, Process and Product Development, Amgen Inc., 1201 Amgen Court West, Seattle, Washington 98119
| | - Christian Schöneich
- Department of Pharmaceutical Chemistry, 2095 Constant Avenue, University of Kansas, Lawrence, Kansas 66047, and Department of Analytical and Formulation Science, Process and Product Development, Amgen Inc., 1201 Amgen Court West, Seattle, Washington 98119
| |
Collapse
|